certolizumab pegol

Ligand id: 6774

Name: certolizumab pegol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol

Compound class Antibody
Approved drug? Yes (FDA (2008), EMA (2009))
International Nonproprietary Names
INN number INN
8448 certolizumab pegol
CDP870 | Cimzia® | PHA 738144
This therapeutic is a TNFα neutralising agent. Structurally it is a Fab' fragment of a TNFα-binding monoclonal antibody, which has polyethylene glycol (PEG) conjugated to a free cysteine residue in its hinge region (Cys227 of the heavy chain). Removing the Fc portion minimizes complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), two reactions known to cause unwanted side-effects in mAb therapies. PEGylation is used to increase the drug's half life, as Fab' fragments are normally rapidly degraded in vivo.
Database Links
Specialist databases
IMGT/mAb-DB 242
Other databases
GtoPdb PubChem SID 178103380
PubChem SID 178103380
Search PubMed clinical trials certolizumab pegol
Search PubMed titles certolizumab pegol
Search PubMed titles/abstracts certolizumab pegol
Wikipedia Certolizumab_pegol